LOS ANGELES, July 28, 2004 (PRIMEZONE) -- Bio-Life Labs, Inc. (OTCBB:BLFE) released an information update on its lead product candidate Carcinoderm(TM), a topical ointment that in the estimation of the Company's management, destroys skin cancer cells in a one-time application without harming surrounding healthy tissue in patients who have been diagnosed with basal cell carcinoma, squamous cell carcinoma and melanoma.
"We believe that a retrospective analysis of our clinical trial results to date for Carcinoderm(TM) as a treatment for various forms of skin cancer is very encouraging," said Nancy LeMay, President and CEO of Bio-Life Labs. She added, "We are looking forward to expanding our research into alternative application and delivery methods for Carcinoderm(TM) to target various solid tumor cancers."
Carcinoderm(TM) has been administered to over 900 patients with confirmed diagnosis of skin cancer via biopsy in what the Company believes are FDA-conforming clinical trials conducted by Bio-Life Labs' Executive Vice President and Chief Medical Officer David Karam, M.D., Ph.D. According to these clinical trial results, over 700 of the study patients had post-treatment biopsies showing no active cancer cells; in excess of 200 treated patients require post-treatment biopsies.
The double blind, randomized, placebo-controlled clinical trial to test the efficacy of Carcinoderm(TM) in the treatment of squamous cell carcinoma, basal cell carcinoma, and malignant melanoma is ongoing. Additional research goals for 2004 for Carcinoderm(TM) are as follows:
-- Define which receptor provides the intake for the Carcinoderm(TM).
-- Define the metabolic pathway for the activation of
Carcinoderm(TM).
-- Define the long-term ramifications to tissue treated with
Carcinoderm(TM).
-- Define which receptor is involved in the transference of
the effects of Carcinoderm(TM) from cell to cell, yet spares
healthy tissue.
-- Define possible uses of Carcinoderm(TM) in the treatment
of other types of tumor cells.
According to the American Cancer Society, skin cancers including melanoma and non-melanoma skin cancer are the most common form of cancer, accounting for more than 50% of all cancers. Rising at an annual rate of 5%, more than 1 million cases of basal cell or squamous cell cancer occur every year. The most serious form of skin cancer, malignant melanoma, is an expected diagnosis for 55,100 persons in 2004. Since 1981, the incidence of melanoma, the most common cancer among people 25 to 29 years old, has increased a little less than 3 percent per year.
About Bio-Life Labs, Inc.
Bio-Life Labs, Inc. is a research-driven biotechnology company focused on discovery, development, and commercialization of breakthrough treatments for cancer, diabetes mellitus, hepatitis C, and other serious illnesses.
Bio-Life Labs, Inc. cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Bio-Life labs, Inc. that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in Bio-Life Labs, Inc.'s business including, without limitation, statements about: difficulties or delays in research, development, testing, obtaining regulatory approval, producing and marketing its technologies and products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; its ability to meet product development objectives; competition from other pharmaceutical or biotechnology companies; its ability to obtain additional financing to support its operations; its ability to attract and retain experienced scientists and management; as well as other risks detailed in Bio-Life Labs, Inc.'s Securities and Exchange Commission filings. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Bio-Life Labs, Inc. undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.